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3Abstract
This paper examines policy issues surrounding patients who suffer from rare diseases
and the implications of the biotechnology ‘revolution’ in relation to priority setting
and rationing in the National Health Service. It shows how the key players in
rationing decisions - politicians, bureaucrats, managers, consumers and the media,
are shaping research into rare diseases and the threat to autonomous researchers by
the increasing centralisation of NHS R&D. It also shows the increasing power of
patient and professional lobby groups to influence policy decisions, aided by the new
information and communication technologies. The lack of government support for
the nascent UK biotechnology industry, in contrast to the USA, not only impacts on
industrial success but may also hinder medical advances. The recent European
Orphan Drug Regulation (2000) and the supporting Framework V programme may
have an impact on treatments for rare diseases. Orphan drugs are defined as
medicinal products for the treatment of rare [orphan] diseases, whose costs of
development are inevitably disproportionately high in relation to the volume of
products likely to be sold, since there are only a few sufferers needing treatment.
Key Words: Biotechnology; Orphan diseases; Technology assessment
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According to Leneghan (1998, pi) the issues that the new genetics will raise for the
NHS have hardly been identified, let alone debated. More recently, Ron Zimmerman
1999 (see Kent 1999), the Director of the Public Health Genetics Unit, reported that
many publications and conferences over the years:
“have recognised the impact of genetics but most, if not all, have focused
on the broader ethical, legal and social implications of genetic science
rather than its consequences for clinical practice”.
Various bodies have produced reports on a variety of policy issues surrounding
screening, cloning, insurance, patenting and genetic [social] discrimination. Wider
issues surrounding research funding, especially for rare diseases, and links with the
pharmaceutical industries and the issue of the development of genetic medicine in an
environment of rationing and priority setting has had little coverage. According to
Hunter (cited in Leneghan, 1998, p1), it is time for a thorough appraisal of the policy
implications of genetic medicine. Even though the technology may be ten years or so
away it is critical for policy makers, managers, practitioners and the public to have an
understanding and knowledge of what lies ahead. It has been agreed that rapid
advances in medical technology will ultimately result in increased rationing (The
Kings Fund 1998, Ruddle 1991, Office for Science and Technology [OST] 1993,
Seedhouse 1994) due to the expected increased expenses of new medical and
therapeutic interventions. Judge 1978 (in Leneghan 1998) identifies five key players
in rationing decisions - politicians, bureaucrats, managers, professionals and
consumers, to which the writer will add the media. Patients suffering from rare
diseases and the non -profit organisations representing them often feel like the
orphans of the healthcare and social systems.  Using Rett Syndrome as a case study
this paper will explore how a minority population is placed to generate basic
research, be of developmental interest to pharmaceutical companies and the barriers
to treatment within the NHS under ‘unwritten’ policies. To determine the scale,
scope and direction of this research a wide literature and Internet search was
conducted on rationing in the NHS, orphan drugs legislation, Rett Syndrome, gene
therapy and the biotechnology and pharmaceutical industry. This search will need to
be ongoing as the area of medical developments changes fast. Lofland’s 1984
‘puzzlements’ technique (see Gilbert 1993, p136) was used to categorise problematic
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identified, which had not been attended to in previous research. The respondents
chosen are the target population of a particular, narrow, research population who are
not known - identification is one of the research aims.
The paper gives the background to the UK National Health Service (NHS) resources
dilemma, and rationing, and the role of the National Institute for Clinical excellence
in technology assessment. NHS access and increased public demand are discussed
and the background to the UK pharmaceutical and biotechnology industry is
compared to that of the United States. The case study, Rett Syndrome, is followed by
the preliminary findings of the paper in respect of the European Orphan Drug
Regulation (2000).
The Resources Dilemma in the UK National Health Service.
 ‘’The government has made it clear that there should be no clinically
effective treatments which a Health authority decides as a matter of
principle should never be provided’’ (Health Care UK 2000, [1995],
p39).
 The King’s Fund (1998) suggests this use of semantics is politician speak for
‘rationing is not inevitable’, that is, rationing defined in this way does not exist.
Whilst NHS funding has increased in real terms, demand is still outstripping supply.
This is not new, first year expenditure estimates of £176m in 1948 spiralled to
spending of £225m (Ruddle, 1988, p3). It could be argued that as long as services are
provided at zero cost to the consumer, then demand is potentially infinite. Added to
these demands are powerful economic and cultural pushes towards a technological
‘quick fix’. New technologies and techniques, whilst reducing costs in some areas
such as key-hole surgery, are mostly cost increasing rather than cost-reducing
(Ruddle, 1988). They may turn out to be ‘flat of the curve’ (Fuchs, 1993, p180)
medicine providing minimal or no health benefits. According to Leneghan (1998,
p123) the problem for policy makers is that the high costs of new genetic
technologies have not been studied thoroughly. A resources dilemma is defined as
the gap between finite resources and infinite demand, which appears to be growing
within health services internationally. Rationing, (usually expressed as
‘prioritisation’, ‘allocation of resources’, ‘cost-effectiveness’ etc), is described by
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services.... and a limited supply of resources” is achieved (quoted in Ruddle, 1991,
p1). The King’s Fund (1998, p89) suggest that priority setting is a synonym for
rationing and that beneficial treatments will continue to be denied, whilst decisions to
allocate funds are often the result of political battles over budgets.
Rationing can be formal, explicit and overt through a prioritisation of need and
positioning on waiting lists or through eligibility rules like breast screening for the
over 50’s. Rationing by geography is where a treatment is only available at one
centre, limiting those able and willing to travel. Rationing can be unofficial and
covert through delays in, or deterrence from seeing a consultant or through a dilution
of services. Rationing by price occurs in the decisions on which technologies or
drugs to buy from pharmaceutical companies. Simply not purchasing a specific drug
rations its use. There may be variations in availability as a result of legitimate clinical
disagreement about the practical effectiveness of laboratory tested drugs. Most
rationed drugs are not cures but may alleviate symptoms, or prolong life, in chronic
incurable degenerative conditions, therefore non-treatment affects quality of life.
Clinicians increasingly have to prioritise resources. Rationing via public relations
means the growing reliance on charitable or private fund-raising to pay for expensive
medical treatment. This dependence is seen as disturbing and deeply problematic. A
report from the Health Advisory Service (1997), reported in the Kings Fund (1998),
found that the most dynamic force for change was the existence of a clinical team
with a special interest, the absence of which meant health, as well as social services,
had to rely on local charities as the main source of expertise, equipment and the
funding of specialist provision. This may be analogous to the ‘special interests’
across the range of medicine, including Rett Syndrome (see below). Practitioners
within R.S. speak of the ‘family of Rett’ to include sufferers, carers, families,
researchers and clinicians. The government will come under increasing pressure as
public knowledge, gleaned via the new media technologies, increases and
consumerism grows.
7 Health Technology Assessment
 The National Institute for Clinical Excellence (NICE) was launched in March 1999.
Its remit is to assess new drugs and techniques and advise ministers on which
treatments are too expensive or insufficiently cost-effective for the NHS to afford. It
will also offer ‘authoritative guidance’ throughout the NHS, whilst disseminating
innovation quickly and effectively (Timmins 31.3.99). NICE will consult a Partners
council, comprising stakeholders (including patients) and will advise on whether new
treatments, drugs or technologies should be adopted. However NICE will not cover
the private sector, which accounts for between 10-30% of medical treatment, so
therefore 10-30% of the data will be missing in any assessment of ‘best practice’
(Timmins 15.3.99). The Commission for Health Improvement (CHIMP) will enforce
clinical governance, to ensure doctors follow NICE guidelines, unless in certain cases
there are good reasons not to (Timmins 15.3.99).
 In launching NICE and talking about the future NHS service, Frank Dobson, the
Health Secretary (www.coi.gov.uk/coi/depts/GDH/coi3738f.ok) did not use the
‘rationing’ (allocation/ priority) word once. Perhaps these terms have been replaced
by ‘the spread of good value’, ‘the degree of clinical benefit’ and ‘good value for
money.’ The medical respondents in this paper suggest that there would be no
problem of NICE recommending treatments for rare diseases, however the treatment
has to be developed first and this thesis has attempted to show the barriers in this
development. The UK Licensing Authority licences any drug shown to be safe,
efficacious and of good quality, with no weighting on cost. It is up to the purchasing
Health Authority whether to purchase expensive drugs passed by NICE, thereby
dictating to clinicians what is available. Health technology assessment can be defined
as the assessment of the costs, effectiveness and broader impact of all procedures
used by health professionals to promote health, to treat and prevent disease and to
improve the rehabilitation of patients.
 There is national interest in innovation and technology transfer. Advances in health
related technologies promise the UK competitive advantage in a global market. The
underpinning of this advantage depends on the rock-bed of basic research, the
exploitation of biotech sciences and the diffusion and adoption of proven advances in
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Technology assessment is a tool of health economists to gauge the cost-effectiveness
of treatments, in the diffusion of technologies gleaned from advances in R&D. The
implementation and exploitation of new technological innovations is paramount to
patient’s health needs and industrial competitiveness. Technology assessment, as a
policy guide, is necessary to evaluate short and long-term safety, efficacy and
outcomes, comparison with any existing options, indications for use, quality and
cost-effectiveness of novel procedures. Technology assessment may be a complex re-
iterative process requiring re-evaluation, for example if new data emerges or the cost
of technology reduces (making it more cost-effective). Pharmaceutical companies
and developers of diagnostic techniques may disregard a promising treatment if they
cannot see a market for it, ethical arguments are therefore very influential.
Researchers cross multi-disciplinary activities, each with its own focus in interest and
levels of skill. Complex areas of research require a multi-disciplinary element in
assessments, which are now more broadly disseminated and under public scrutiny via
the mass media.
Randomised trials are still the preference of many clinicians being critical of
technology assessment’s scientific credibility. However according to Fuchs (1993,
p182)
“Even expertly designed clinical trials...may not yield clear, quantitative
answers concerning the effectiveness of a new diagnostic or therapeutic
intervention”.
Complexity invites errors, even with the greatest care. Multi-disciplinary research
means evaluators reliance on other ‘experts’ such as journal reviewers, who might
fail to detect errors due to a lack of essential data, inadequate analysis or
misinterpretation of results. The value of technology is dependent on the clinical
setting and consumer preferences, requiring consideration rather than a yes or no
response. Non-physiologic factors like quality of life, ethics etc. are difficult to
incorporate into an analysis, which may lead to errors in evaluations.
9 There are fears amongst medical researchers and the medical technology and
pharmaceutical industry that technology assessment will inhibit the development and
diffusion of new products (Fuchs 1993, p182)
 NHS Access
 Private health insurance is available to those who want to (or can) pay. Many
government reviews have surrounded the implementation of an insurance based
system, similar to the US system, of healthcare but has been rejected as being a
viable alternative (Ruddle 1988). Meanwhile patients are ‘locked in’ to what is
‘available’ under a state monopoly. According to the Office of Health Economics the
UK health expenditure, as a percentage of GDP, in 1999 was less than half that spent
in the US. Other EU countries spend far more of their wealth on healthcare, although
some of the difference can be accounted for by private health insurance schemes.
According to the Pilling (13.4.99) it appears that the US health insurance industry
appears more willing to pay for treatments than governments, leading to a boom in
the US domestic drug market over the last twelve months.
 Politicians take macro-level decisions but are also involved in micro-level
conditions, when called upon to intervene on a constituent’s behalf or to enhance
public relations. The media increasingly bring pressure to bear on decisions
concerning high profile cases, especially cases involving children denied treatment or
suffering delays. In these cases resources may have to be diverted from elsewhere,
denying some-one else treatment to retain the veil of political ‘correctness’.
 In the UK there is no legal right or precedent to treatment. Test cases have been
brought under the 1977 NHS Act but the courts, in general, have not found for the
plaintiff. The legal system cannot be used successfully unless the government issues
more explicit rules about how the NHS should ‘set priorities’ (‘ration’, ‘allocate’)
and the specific responsibilities of the NHS. Healthcare 2000 (1995) suggests it is
generally agreed that the principles of the NHS are:
• Universal access.
• Highest quality, professional standards applying up to date knowledge.
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• Treatment based on clinical need without regard to the patient’s ability to pay.
• A service responsive and sensitive to the needs and wishes of patients and
carers.
 The issue is how do you define need as distinguishable from wants and demands. The
whole definition of the NHS ethos is in crisis. Ruddle (1998, p21) suggests that:
 “The incommensurability of values means that it would be impossible to
develop a rational model for rationing resources in the NHS”
 Ruddle (1998) also suggests this is why rationing decisions are usually made in an
ad-hoc reactive way, which supports Richardson (1994 p.65). Resources, at the
micro-level, are allocated from the top down to different competing services. Each
service then has to decide on the budget allocation. This allocation mechanism will
directly affect decisions taken on the ‘front line’ by consultants and doctors, who face
an ever increasing level of expectant demand from an ever more aware,
knowledgeable and belligerent consumer. It is on this micro-level front line that
rationing is most overt. Macro level rationing decisions are covert, there are no
written rules so according to Ruddle (1991, p13) the issue is ‘fudged’, in the sense
that there is “no co-ordinated, consistent, national criteria for rationing”, perhaps
because of the risk of a public backlash. Doctors are between a rock and a hard place,
they want to do the best for their patient and retain clinical freedom, whilst relegated
to acting as a gatekeeper to limited resources in what is, in effect, a local monopoly
or ‘closed shop’. There is a flood of information in the media on diseases and
medical advances. On the Internet there are medical sites, chat rooms and virtual
pharmacies. Pharmaceutical companies are advertising their ‘wonder products’ to an
ever increasing audience (Pilling 20.3.99). Consumers may demand, with combined
pressure from relatives and Non Government Organisations (NGO’s) the ‘very best’
new treatments.
 The UK Pharmaceutical Industry and Biotechnology
 According to the Financial Times Biotechnology Survey (6.10.98) we are in the first
stage of a biotech revolution, the aspiration of which is to find the cause of diseases
and develop cures and enabling therapies. Pre-1993 all drug discovery by all the
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pharmaceutical companies put together had worked on an estimated 400 ‘keyhole’
drug targets. Today they work on 400 per. year, due to an explosion in new
technologies. The issue is the pace and breadth of this revolution and how quickly we
can harness the results.
 In 1999, the UK pharmaceutical industry was the third largest exporter in the UK
with exports of about £7b, employing 30,000 people (OST 2001) This global industry
is hampered, in competition with the US, by different patent laws. The US advantage
allowing a twelve month breathing space before the lodging of a patent, UK scientists
are pressured to patent immediately - leading to restrictions on interactions between
academia and industry. There also appears to be a development gap between research
and industrial application in the UK. The cause of this gap appears to be ‘differences
in perception between academia and industry in what constitutes an exploitable
invention’ (OST 1993). Academia, industry and the NHS need a successful
partnership in order to exploit all possibilities. Collaborative ventures, as found in the
US, leading to a greater understanding of the potentiality, may be engendered
especially in newer areas of research, such as gene therapy. OST (1993) points to
comparisons of the UK industries reticence, and the US enthusiasm for, new product
innovation and keen approach to long-term investment. US pharmaceutical
companies, whilst having strong links to US research centres, have also set up
parallel research programmes alongside UK universities, for ‘mutual support’. The
US operates what is essentially a market-based health care system, reforms driven by
powerful market forces. Competition and free market entry are said to allow
consumer choice. Prices tend to settle at a level people are willing to pay and
products are designed to meet consumer needs. In the U.S. whilst costs are rising
again it is thought that regulations and restrictions, imposed top-down, via
government policies, are not in the interests of patients (who are becoming more
educated and vocal about restrictions in health care). It is suggested that policies
should be introduced that make the market work better. The rapid acceleration in
medical technology is leaving policy makers behind. An open, informed and
competitive market, within which patients are not passive recipients but have rights
responsibilities and choices, may require an expansion of the private health sector in
order to cope.
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 According to the Pilling (13.4.99), by 2002 only three of the world’s top 25 drugs
will be of European origin, as opposed to 50% a decade ago. The reason is seen, not
in research but in the squeezing of drug budgets, forcing downward pricing, and the
malaise in the approval of new (more expensive) treatments - giving a poor rate of
return on research investment and creating a disincentive to innovation.
Pharmaceutical companies are currently investing up to 20% of their overall R&D
budgets (typically 20% of revenue) in increasing symbiotic alliances (see Appendix
B) and joint ventures with, or equity stakes in, biotech companies, whilst embracing
some of the platform technologies such as genomics, combinatorial chemistry and
high throughput screening.
Background and Context to Rett Syndrome
This paper concentrates on a specific condition, Rett syndrome, (the sufferers of
which may benefit by new interventions in the future). Rett syndrome (estimated to
affect 1: 20,000 of the population) is a rare neurological condition, which
overwhelmingly only affects females, caused by a mutation on the X chromosome at
site Xq28 on the human genome, usually lethal to male foetuses. The incidence of
Rett Syndrome is the same across all the social, racial and cultural groups of the
world. Life expectancy, in the affluent Western countries is into the 40’s, however
there are cases of sudden death, caused by respiratory arrest and heart failure together
with deaths from other causes such as pneumonia or seizures.
 Rett Syndrome was first reported in 1966 by Dr, Andreas Rett, an Austrian clinician.
His attention was drawn to two young female patients, sitting in his waiting room,
exhibiting similar ‘behaviour’. Dr Rett unfortunately published his findings in
German, therefore his paper was not widely read. Rett Syndrome was ‘re-discovered’
in 1983 by Bengt Hagberg, a Swedish paediatrician who, when presented with a
patient displaying certain characteristics, recalled an earlier meeting with Dr Rett and
realised his patient displayed similar symptoms to those described by Dr Rett. Dr.
Hagberg then published an article in English on this ‘new’ syndrome, which he
referred to as Rett Syndrome (see appendix A). New techniques in molecular genetics
with the identification and diagnosis of genetic disorders, with pharmaceutical
innovations, offer a future potential treatments whilst genetic tests can be used for
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prenatal and presymtomatic diagnosis, carrier identification and DNA profiling. It
appears protein based pharmaceuticals would seem to be the most expedient hope for
Rett Syndrome sufferers, using recent innovations such as combinatorial chemistry,
high throughput screening and bio-informatics. Genomics, pharmacogenomics and
proteomics will enable the proteins produced from genes (once identified) to be
studied and tested for therapeutic use, using tailored drugs. According to Kent (1999)
where interest has been shown by biotechnology and pharmaceutical companies, it
has been in the common genetic disorders.
 Research Design and Methodology
 To determine the scale, scope and direction of this research wide literature and
Internet searches were conducted on rationing in the NHS, orphan drugs legislation,
Rett Syndrome, gene therapy and the biotechnology and pharmaceutical industry.
From this areas of interest were identified, which had not been attended to in
previous research. The respondents chosen are the target population of a particular,
narrow, research population. There is still major debate regarding the virtues of
qualitative research as compared with quantitative methodologies. I chose to use
qualitative methods to conduct non-standardised, semi-structured, in-depth
interviews. This method was chosen based on the limited resources and time
available. A control sample cannot be compared with an ‘affected’ sample due to the
emotional issues involved. Although using questionnaires, to elicit information from
carers, would elicit rich information this was felt to be unethical. Questions
concerning research and possible treatments may raise false hopes in a vulnerable
population. Such complicated issues are not amenable to questionnaires or structured
interviews to gain sufficient depth amongst a minority population, who may be
difficult to identify. The subject matter in this case excludes the vast majority of the
population.
 A simple design, at micro-level was needed that parallels social conversational
‘norms’ - allowing a more in-depth investigation (see Lofland, 1971, ‘guided
conversation’, in Gilbert, 1993, p136). Also this approach may allow the ‘study’ of
participant’s motivations. There was a need for a flexible approach to a complicated,
perhaps sensitive, area. This required a strategy for discovery of detail. One-on-one
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interaction reduces suspicion, allowing a genuine interplay between researcher and
respondent. Pilot interviews were not felt practical as the respondents selected were
high status professionals whose time is very valuable, although returning to
respondents may be possible for clarification if needed. The approach involved
informal interviews with a professor of genetics, a leading clinician and a
representative from the biotechnology industry. The standardisation of interview
‘discourse’ may be problematic, each respondent is a unique individual, representing
a different discipline and background. It may not be possible to isolate cause and
effect, or to generalise from the outcome due to the specific nature of the topic.
However transcripts were made of each interview, to enable a full and accurate
record for scrutiny during later analysis and, following Gummesson (1991), to
enhance the reliability and generalisability the accuracy and credibility of the findings
were confirmed by the interview subjects.
 Preliminary Findings: NHS Priorities, R&D and Increasing Accountability of
Regional Genetic Centres (RGC)
 In the UK the NHS is the major purchaser and consumer of health care technologies
and the main beneficiary of medical and health related R&D achievements.
Clinicians in the NHS provide a dual role as users of new technologies and the
development of innovative basic research, together with researchers in Higher
Education Institutes (HEIs) which is fed to industry for further development.
Successful partnerships between academia, industry and the NHS are the seed-bed of
UK competitive strength and provide future benefits in the quality of life of UK
citizens.
 In the UK there are currently on average only 1.4 consultant clinical geneticists per
million population. There are around 5000 diseases that are individually rare but
collectively represent a significant number of patients. The workload of RGCs is
increasing due to an increase in recognised genetic conditions and an expanding
demand from patients (or relatives) having an increased awareness and expectation
brought about by media reports.
15
 There is no official definition of what genetic services should comprise however the
activities of the Regional Genetic Service include running genetic clinics,
counselling, maintaining genetic registers, the training of clinical geneticists,
undergraduate and postgraduate education, research, liaison with genetic laboratories
and providing expert advice to clinicians in other specialities.
 It has been difficult to determine reality from media hype as industry and some
researchers have been quite happy to fuel these expectations, thereby increasing their
profile and share prices or easing access to research grants. According to the
geneticist the media also play on the publics emotions, for example highlighting
campaigns for increased resources for premature babies. The response of the NHS is
seen as a ‘knee-jerk’ response to media reporting, allocating resources to popular
diseases. Finite resources mean that for every decision made about resource
allocation there is an opportunity cost. Money spent on ‘popular’ diseases cannot be
spent elsewhere. It appears that research into rare diseases is still being done
regionally on an ad-hoc autonomous basis, dependent on the researchers particular
interests based on knowledge of, or association with, a patient or patient group
(which supports Blank 1988). It has been suggested that less of this research is being
done due to the NHS priority in service delivery and research into common diseases,
rather than focused biomedical research. This has reduced the funds available to
specialities such as the Regional Genetic Services, creating immense problems for an
‘orphan’ service, which continually has to justify research. Getting actual research
funds is described as a nightmare, having to try national bodies like the Medical
Research Council or numerous outside charitable organisations. This means if you
are a member of an organisation representing a rare disease you are unlikely to have
enough funds to either 1) be approached or 2) be able to pay for research.
 Research is done on an ad hoc basis by researchers who are allowed a measure of
autonomy within the NHS or by academic and medical researchers funded by
government research institutions like The Medical Research Council or charitable
bodies such as the Wellcome Trust. The writer has previously shown that there are no
formal projects undertaken into rare diseases or Rett Syndrome in particular by the
research councils or the NHS. So rare diseases will have a low priority, even if they
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are more debilitating than certain common diseases that may already have some form
of treatment.
 Rare diseases, at least at the regional level are not prioritised (other than perhaps
through investigators interests - there must be some level of discrimination due to
human nature). The accepted method in applying for funding is to look at groups of
similar disorders as experience has shown that applying for funding in this way has a
better outcome. The power of small associations is through collective lobbying as
shown by EURORDIS, NORD and GIG (see appendix A) and professional
organisations like the JCMG (see appendix A). One must question who ‘shouts
loudest’ even within this. There is bound to be a dominant group pushing personal
self-interests. There is an emotional lobbying power in that genetic disorders affect
children, which can be a powerful media projection. However, perhaps not as
appealing as premature babies or children with cancer. The RGC know the pressing
needs of families with genetic disorders but it is difficult to get that across to an
increasingly cash-strapped health service administration when there are so many
other priorities.
 The advances in genetics may soon threaten RGCs specialisation in rare diseases as
the emphasis on genetic research is concentrated on the causes and cure of common
conditions found to have a genetic cause. As medical researchers in the NHS become
more accountable to the Central Research Council (CRC) autonomous research may
disappear, with pressure to move to NHS priority areas in common disorders (for
example cancer, Alzheimer’s and heart disease). The RGC is already constrained by
limited NHS funds, creating opportunity costs. In addition to maintaining established
services for rare diseases they are faced with new projects such as the genetic
component of the multidisciplinary provision for cancer genetic services.
 The Regional Genetic Service has no current joint research projects with pharma or
biotech companys, which may, in the future, be an avenue worth exploring. However
the feeling is at the moment that pharma / biotech companies are only interested in
the ‘big hits’. Hopefully the recent European Orphan Drug regulation may encourage
new links between industry and the research base, at the genetic service level. A
small biotech company would do well to collaborate with researchers in the Regional
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Genetic Services. The background research to this thesis uncovered a vast amount of
research ongoing in the US, into rare diseases. There may well be research being
done into Rett Syndrome in the UK that is subsumed under ‘umbrella’ projects but
information is either not available or impossible to untangle.
 It was felt to be impossible for NICE to devise a national service framework for
every single speciality, for every single disease but that a kind of generic standard
will be set. If a treatment came available for a rare disease it might actually be
funded. Standards for situations are being drawn up by the genetic profession to
present to NICE as a fait accompli. It seems that if a treatment is discovered for Rett
Syndrome that as long as NICE is not backlogged with other work it may well be
fully endorsed and available with no geographical bias. However there would be
nothing to stop a clinician prescribing treatment without NICE’s blessing. CHIMP,
the NHS inspectorate is very unlikely to influence the use of such (hypothetical)
treatment. However the possible closing down of autonomous research under
centralisation may hinder a treatment being found for a rare disease in the first place.
 NICE has proven controversial in its conclusions regarding various drugs, devices
and technologies it ‘tests’, however it may allow the NHS progressively to set
priorities in a much more rational way than has been possible to date. Policymakers
need to be predictive if not prepared, in their approach, in order  to understand the
ways in which patients may react to the potential choices offered by new
technologies. It may be impossible to predict how genetics and biotechnology
develop. Planning for the future involves uncertainty but requires a clear
understanding of the principal factors that shape policy making. The less that is
known about the future pressures on NHS resources the greater the need for inclusive
debate on rationing and the principles of the NHS. According to Hunt (cited in
Leneghan, 1998, p5), the subject has hardly been considered by those who advise on,
or formulate, national health policy.
 UK Research and Industry Links UK Funding of Genetic Research
 The Human Genome Project (HGP) is not an end in itself and it could be argued that
this project has taken resources from the basic biological research needed to interpret
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the information it has produced. Assessment of the total funding for genetic research
is difficult as genetic research crosses the broad range of science. Little funds are
allocated to genetic research by the NHS due to the MRC contribution. The NHS
R&D programme only spent £1.1m in 1995/6 on research into diseases of genetic
origin and their consequences. The NHS does however provide some of the
infrastructure costs of clinical research, which allows the universities, the MRC and
medical research charities to operate within the NHS. The Wellcome Trust has been
recognised by the House of Commons Select Committee on Science and Technology
(1995) as sustaining both basic and applied research in the UK, contributing more
than £400m a year overall to medical research, conducted in academia, hospitals and
pharmaceutical companies. The committee acknowledges that ‘without the support of
the Wellcome Trust and other charities genetic research in this country would be
severely under-funded’. In the increasingly competitive climate for research funding
researchers are chasing ever-shrinking resources. Funding agencies currently only
support 15-20% of applications. According to Goldblatt (1997) the MRC is more
interested in grants to centres and collaborative funding to UK research projects. This
may deplete funds available to ‘isolated’ research interests or international networks.
There are approximately ninety-six charities that fund medical research in the UK.
Many support single rare diseases, with an average budget of less than £1m. The
smaller charities (like the RS Associations) have budgets measured in £1000s.
 The Clinician’s Viewpoint
 The clinician confirmed that the current prevalence of Rett Syndrome (1:10,000) may
well now be just the tip of an iceberg. Rare diseases and Rett Syndrome in particular
may be an attractive proposition to pharmaceutical or biotechnology companies who,
whilst developing a drug for a minority disease may hit the jackpot if, as may be the
case, that Rett Syndrome is the greatest cause of mental handicap in females.
Diagnostic tools may also find more boys who have a form of Rett Syndrome. The
clinician has approached drug companies who have helped fund dinners, host
scientists meetings and helped with travel expenses. They seem rather reluctant in
offering R&D or clinical trials even where drugs have been identified as possible
candidate treatments by independent Rett researchers. The clinician suggested that
research is frequently based in the NHS, with many practitioners working on specific
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interests in their own time. The NHS also supports research by establishing joint
posts where holders divide their time, in a symbiotic relationship, between hospitals
and universities. The NHS benefits from the research resources available at the
universities and the universities benefit by a steady stream of medical tutors and the
knowledge, which comes from practical experience. Genetic research is often based
in Universities, the balance covered by private initiatives. Interested researchers in
rare diseases are geographically dispersed and as in Rett Syndrome for example are
often international. Individual clinicians encourage networking and collaboration.
These net-workers not only share information but also tissues (from the rare cases of
Rett Syndrome that result in sudden death), donated by next of kin who have taken
the brave step of organising special autopsies.
 Increasing numbers of diseases previously thought as non-genetic in origin are being
found to be linked to certain genes. Biotechnology companies are increasingly
involved in this process but are constrained by a shortage of R&D funds. Whilst
collaboration between academia and industry and within industry itself is critical to
the success of the UK biotechnology industry according to the House of Commons
Select Select Committee (HCSSC 1995) two of the key factors impeding the
development of the biotechnology industry in the UK are:
1. The relative ease and enthusiasm with which US researchers, as opposed to UK
researchers, sought application of their research and collaborated with industry.
2. The reluctance of pharmaceutical companies to collaborate with British
companies or academics.
The clinician has had little support from industry, which may show that little
improvement in collaboration, on rare diseases in particular, has been made possible
since the Select Committee report in 1995.
 There is evidence of how dedicated professionals use their own time to pursue their
research and how informal networks have been set up which cross international
borders. There is evidence of the barriers researchers (identified in the writers
research) face in obtaining either funding or industrial interest and how important
charities, especially the Wellcome Trust, are to the UK medical research base.
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 Industry’s Perspective
 European patient groups played a major role in negotiations in the passage of the
European Orphan Drug Regulation through the political process, having gained a
larger voice by uniting into lobby groups, similar to the American experience, which
merits an introduction here (see Appendix C). In the US, under the Orphan Drug Act
of 1983 and subsequent amendments, incentives are given such as:
• Exclusive marketing rights for 7 years after the approval of the orphan drug
developed for a disease that affects < 7.5: 10,000. (The Japanese Orphan Drug
Act of 1993 relates to diseases that affect < 4: 10,000).
• Tax credits (up to 50%) for clinical testing of orphan drugs.
• Grants and contracts to support clinical and pre-clinical orphan drug research.
• Flexibility and assistance in regulatory processes.
 Prior to 1983 only ten drugs had been developed for orphan diseases in the previous
decade. In 1991 there were 189 in development. Some of these drugs have since
proved to be extremely profitable, being found useful in more common disorders.
The European Orphan Drug Regulation came into affect in June 2000. The regulation
allows an exclusive ten year distribution right as an incentive to pharmaceutical
companies to develop ‘orphan drugs’ for the cure or alleviation of diseases that affect
<5: 10,000. EU authorities will also assist in clinical trails and help to obtain licences
and cover designation fees. It is hoped that this regulation will stimulate interest in
the orphan drug market in Europe, similar to the effect of the US and Japanese
initiatives. This will be discussed later.
 Research and Development Within Biotechnology Companies.
Within biotech companies contacts, or association with a patient, patient group or
family member are becoming an important catalyst to R&D. Orphan drugs or
possible treatments for rare diseases often result from personal contact, or association
with, a patient or patient group or family member. Within larger pharmaceutical
companies R&D for orphan diseases more often arises from the testing of established
drugs which are found to have an unexpected effect (serendipitous discovery) which
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might be useful in specific situations. However even with orphan drug incentives
some diseases are too rare to ever interest a company unless the enormous market
prices were passed on to the patient or provider. It is possible that the treatment may
be later found applicable for a commoner disease but the financial risks are too high.
Most basic research is not done by the actual company (that may develop a
treatment), but is usually done within government institutions. It would appear the
research done is reflected (again) by a researchers particular interest.
“Some researchers even look specifically for rare diseases because they
think that through a rare disease finding they can then go to a common
disease later on and find similarities there” (respondent).
There have been accusations in the media about companies exaggerating the
potentialities of new drugs and being completely profit oriented. However in
discussion with patient groups, the biotechnology industry has agreed to approach the
press in future only over realistic expectations. Companies are in business to make
profits, to attract investors, to expand. However, there is no necessary conflict
between altruism and being profit oriented. Industry is itself a component of society,
which contributes to society. Industry is not separate from society, it is a part of it.
Industry has a responsibility therefore to that society. Corporate governance means
more and more companies are looking at their societal role as being an important part
of their integrated development.
Discussion and Conclusion
Biotechnology companies (being small enough to concentrate on smaller projects)
may be the salvation of sufferers of rare diseases. The European Orphan Drug
Regulation has to be followed by the UK government and may be the stimulus UK
biotechnology companies need to compete with US biotechnology companies in the
orphan drug market. The evidence given in Appendix C shows the American Orphan
Drug Act was more an act of the people and the media rather than any ‘policy
decision’. European lobby groups contributed greatly to the progress of the European
regulation. This shows the power of united lobby groups and the media the writer has
alluded to previously.
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As Information and Communication Technologies (ICTs) have proved powerful
organising tools for scientists, in the new bio-informatics, so too have they become
an organising tool for public concerns. ICTs and the media are allowing mass
communication, synchronously and asynchronously, facilitating organised mass
lobbying. Rather than ICTs disenfranchising citizens in a decline of the public sphere
(Habermas 1997) it can be argued that ICTs have allowed disenfranchised citizens to
become better informed within a high-speed public sphere of communication never
witnessed before. As these networks become more accessible and attract interested
parties we may witness a decentralisation of government policy setting, to powerful
lobbyists combining public, charitable and scientific communities. The strength of
these lobbies will be a reflection of the ‘strength’ and determination of its members.
The champions of rare diseases are ‘angry’ and therefore very determined, as can be
seen in the American execution of the Orphan Drug Act (1983) and the influence of
NGOs in the implementation of the European Orphan Drug Regulation (2000). As
more patients obtain more information about their medical condition and what is
available world wide, politicians and managers will need to become more explicit
about priority setting and include society in the policy process.
The UK system of government is representative, as opposed to the US system of
participation, which is perceived as having created a more open climate and
improved scrutiny of public decision making. The US gave its citizens a statutory
right to access official information in 1966. The 1999 UK Freedom of Information
Act has been accused of being littered with catch-all exemptions and a gross dilution
of the radical 1997 White paper which promised to make the UK one of the world’s
more open governments. Science and politics remain a closed shop, remote from
‘humanity’ or the ‘citizens’ they purport to represent. The media meanwhile, often
sensationalising a story, supply ‘information’ to the public.
The US system of democracy is much more open than the UK, allowing citizens to
address the Senate. These include Kathy Hunter, the President of the International
(US based) Rett Syndrome Association (IRSA), who has learnt to use the media to
good effect. She has recently been elected to the National Advisory Neurological
Disorders and Stroke Council, the major advisory panel of the NINDS. It would be
interesting to suggest this is why Rett Syndrome is a priority in the US, where a
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mother of a Rett Syndrome child who, like Abbie Meyers the Tourette syndrome
mother, ‘got mad’ and decided to do something not possible in the UK where the
government is closed, dismissive and remote. For a cure for a rare disease to be
found research has to be done and I hope I have shown that this is being done,
probably on a larger scale than officially known and recorded, whereas much
information is not available and many researchers may be doing this research in their
own time.
The EU Orphan Drug Regulation came into force in June 2000. Medicinal products
in this case are those products intended for the diagnosis, prevention or treatment of a
condition affecting <5:10,000 persons in the European Community, where no other
product is in existence. However, according to Article 3 Paragraph 1 of the
regulation, a candidate may be given orphan status even when other methods of
treatment are available, provided that the candidate will be safer, more effective or
otherwise clinically superior. It is thought that commercial incentives under the
Regulation, in the form of exclusive marketing rights and tax incentives may
encourage increased commercial investment in products for rare diseases, in line with
successes in the US and Japan who have established orphan drug policies.
Rare diseases have also been identified as a priority area for Community Action
(1999-2003) within the Framework V Programme. Decision no. 1295/1999/EC
includes actions to provide information, to deal with clusters of rare diseases in a
population and to support relevant patient organisations. The Framework V
Programme for R&D funding promises to provide substantial funds for research into
rare diseases and ensuring a consistency and complementarity of action between
Community Action and the Orphan Drug Regulation. Member states are invited to
introduce incentives for R&D work on orphan medicinal products and for placing
such products on the market, within the framework of their own powers and
responsibilities. In the US it has been found that most applications for Orphan Drug
status are filed by small firms, specialising in biotechnology and genetic engineering,
since the vast majority of rare diseases are developmental genetic disorders.
How policy decisions will incorporate EU regulation and the Framework V
programme is not known. What appears evident is the need for involving the public,
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industry, academia, the media and government, the NHS and research councils in a
public sphere of debate.
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Appendix A: Overview of Organisations and Associations
EURORDIS  (www.eurordis.org) is the European Association for Rare Diseases. A
supportive, collaborative group of 126 patient associations throughout Europe which
advocates for the development and access to new therapies. It also seeks to promote
research and accessible information for those it represents.
NORD  (www.rarediseases.org)  is the National Organisation for Rare Diseases in the
US, a coalition of rare disease organisations. Acting as an information clearing house
it deals with around 700,000 calls and letters together with an additional 210,000+
enquiries to its Internet site. NORD has become a powerful patient representative
group with alliances with manufacturers, voluntary organisations and the US
government - NORD has become a potent political force in the US Congress, where
public participation in debate is commonplace. NORD was founded in the early
1980’s by ‘one mother {Abbie Meyers} who got mad’ about the non-availability of
necessary drugs for her sons condition.
GIG  (www.gig.org.uk) is the Genetic Interest Group which is a UK alliance of over 120
charities that support children, families and individuals affected by genetic diseases.
GIG lobbies on behalf of its members to promote awareness and understanding of
genetic disorders, to stimulate R&D and service development.
JCMG  (www.bshg.org.uk/jcmg.htm) is the Joint Committee on Medical Genetics which
represents the Royal College of Physicians, the British Society for Human Genetics
and the Royal College of Pathologists. Part of its remit is to “discuss and co-ordinate
advice to government and other bodies on policy and service issues relating to
genetics in medicine”.
RSAUK is the Rett Syndrome Association UK, a registered charity and support








Source: Financial Times 13.4.99.
 
Appendix B: Number of announced R & D alliances by top 20 drug firms
























Appendix C: A Brief History of the US Orphan Drug Act
 Mar-1980  Senator Henry A Waxman of the United States Congress was  
  approached by a constituent whose son's condition (Tourette syndrome)
  required treatment with a drug called Pimozide. The drug was  
  approved in Canada but not in the US, so the son's drugs had been
  confiscated by US Customs. The mother, Abbie Meyers, asked Mr Waxman
  “I have only eight days of Pimozide left for him. What are you going to do
  about it?”       
 Jun-1980  Senator Waxman began a series of Congressional hearings at which citizens
  with rare diseases addressed Congress regarding the problem of unavailable
  treatments for their conditions.     
  Newspaper and magazine stories appeared, explaining the dilemma of
  people suffering rare and often debilitating if not deadly illnesses.  
 Mar-1981  A famous television star, Jack Klugman, who starred in 'Quincy' as a medical
  examiner had been moved by the orphan disease dilemma and, knowing
  the power of the media, produced an entire episode surrounding Tourette
  syndrome. Members of Congress began to be lobbied by the public. The
  Congressional hearing drew national media attention to orphan drugs.
 Mar-1982  Survey results on orphan drugs were presented, engendering public support
  but opposition from the Pharmaceutical Manufacturers Association (opposed
  to any government intervention) and the Reagan administration (opposed to
  financial incentives from treasury funds).    
 Sep-1982  The Orphan Drug Bill was put together by politicians, patients and other
  interested parties and passed by the House of Representatives but was
  hindered in its journey through the Senate by senators opposed to tax credits.
  Again, Jack Klugman (Quincy) intervened using the passage of the Bill as a
  storyline.This brought increasing pressure on the Senate who then passed
  the Bill unanimously. However there was still the risk of a Presidential veto,
  recommended by the Treasury Dept. When word was leaked, of a possible
  veto, patient organisations (now united under NORD) another nation-wide
  media focused campaign strengthened public support. “Over forty news-
  papers wrote editorials supporting the Act. Radio stations carried hourly
  reports on the fate of the Bill. Thousands of letters and phone calls poured
  into the White House. On the tenth day, the last possible day for the
  President's action, the Act was signed and became law”
 Henry A Waxman (1982)
 
    
 Source: Adapted from Scheinberg & Walshe (1986)
